Savolitinib for Treating Gastric Cancer and Esophagogastric Junction Adenocarcinoma Patients

Summary

Treating Gastric Cancer and Esophagogastric junction adenocarcinoma Patients with MET gene amplifications with Savolitinib

Timeline

Start

2021-07-27

Primary completion

2026-04-21

Completion

2026-04-21

Publications

• Peng Z, Liu T, Wang H, Wang J, Liu H, Ye F, Li E, Zhang J, Liu B, Lin R, Zhou A, Liu Z, Xu H, Wang Q, Niu Z, Yuan Y, Qin Y, Qu X, Bai Y, Liu N, Liu H, Bai C, Pan Y, Wang S, Wu T, Pan Q, Zhong D, Lu H, Wang J, Wang Z, Deng T, Gou H, Huang X, Fu S, Lu P, Yu J, Hong M, Xu Q, Wang L, Ren Y, Fan S, Shen L; Savolitinib in MET-amplified gastric or gastroesophageal junction adenocarcinoma study group. Savolitinib in MET-amplified gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial. Nat Med. 2026 Jun 1. doi: 10.1038/s41591-026-04459-7. Online ahead of print.

Drugs

Indications